IXICO to present at 10th Annual CNS Summit 2019

IXICO today announces that it is scheduled to attend and present at the 10th Annual CNS Summit held from 31st October to 3rd November 2019 in Boca Raton, Florida, USA.

10th Annual CNS Summit 

31st October - 3rd November 2019, Boca Raton Resort, Florida, USA

Robin Wolz, Senior Vice President of Science & Innovation at IXICO will present a poster entitled "Automated sleep-wake prediction from wearable sensors using neural networks - from data collection to algorithm development, cross-validation and clinical trial deployment" during the evening receptions on Friday 1st and Saturday 2nd November 2019.

This study shows how AI technology improved the analysis of sleep/wake accelerometry from wearables compared to traditional, count-based measurements in a robust and reproducible way. Thus, the exploratory use of this validated algorithm in clinical trials is feasible and provides the collection of evidence needed to support further development of real-world evidence in clinical trial designs. 

The rise in people using connected wearable devices has opened the door for the medical field to harness real-time patient health data to support clinical development of many diseases including Alzheimer's and Parkinson's disease.

Founded by R&D leaders, the CNS Summit is a platform of industry leaders working collaboratively to shape the future of the life sciences with a focus on innovation and technology. The agenda features top leaders from the regulators, pharmaceutical and biotech companies, technology and services companies driving change in the healthcare sector.

Poster authors:

Robin Wolz1,2, Luis Peraza1, Richard Joules1, Yves Dauvilliers3

Affiliations: 1- IXICO, London, UK, 2- Imperial College London, London, UK, 3- Department Neurology, Centre Hospitalier Universitaire, Montpellier, France

About CNS Summit

CNS Summit is a platform for change and a community passionate about shaping the future, with a focus on collaboration, innovation, and technology. Its mission is to have a positive impact on the success of clinical development programs. CNS Summit believes this mission is its ethical duty to the patients they serve by developing new treatments.

Date: 30/10/2019